FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:601 February 29, 1996 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Walter, E. A. PubMed Citation

To the Editor: The article by Walter et al. (Oct. 19 issue)¹ provides important evidence that the infusion of donor–derived CD8+ cytotoxic T-cell clones specific for human cytomegalovirus proteins can promptly reconstitute cellular immunity against human cytomegalovirus in recipients of allogeneic bone marrow, thus reducing the risk of morbidity and mortality related to viral infection. However, we would like to comment on two points.

First, excretion of the virus in urine and its isolation from the throat have not been demonstrated to be predictive of cytomegalovirus disease in humans,² and consequently these measures should not be used to monitor infection . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Sobulo, O. M., Borrow, J., Tomek, R., Reshmi, S., Harden, A., Schlegelberger, B., Housman, D., Doggett, N. A., Rowley, J. D., Zeleznik-Le, N. J. (1997). MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc. Natl. Acad. Sci. USA 94: 8732-8737 [Abstract] [Full Text]  
• Rowley, J. D., Reshmi, S., Sobulo, O., Musvee, T., Anastasi, J., Raimondi, S., Schneider, N. R., Barredo, J. C., Cantu, E. S., Schlegelberger, B., Behm, F., Doggett, N. A., Borrow, J., Zeleznik-Le, N. (1997). All Patients With the T(11; 16)(q23; p13.3) That Involves MLL and CBP Have Treatment-Related Hematologic Disorders. Blood 90: 535-541 [Abstract] [Full Text]